Home > Press > Iran Presents New Anti-Cancer Nanodrug to Market
Abstract:
Iran presented to the market on Wednesday a new home-made nanodrug for chemotherapy, giving cancer patients a new hope.
"The first home-made chemotherapy drug produced by utilizing nanotechnology was presented to the drug market today and can be used by gastrointestinal cancer patients," Iranian Deputy Health Minister for Food and Drugs Affairs Ebrahim Sheibani told reporters on Wednesday.
He said that after the domestic production of the nanodrug, Iran's imports of chemotherapy medicines have decreased by $5mln.
Noting that Iran is now producing 97% of its drug needs, Sheibani said that despite the western sanctions against Tehran, the country is not faced with any crisis in providing chemotherapy medicine for the patients.
Iran has made huge achievements in various fields of science and technology, from nuclear knowledge to stem cell and Nano technology.
In a most recent case, Iranian Health Minister Marziyeh Vahid Dastjerdi announced in September that the country would soon start production of 15 types of anti-cancer drugs.
"15 types of monoclonal anti-body drugs are being synthesized with the help of the Scientific Department of the Presidential Office, using hi-tech technology," Vahid Dastjerdi said.
Also earlier this year, Iranian scientists succeeded in producing new types of medication for treating different kinds of cancer, viral diseases and arthritis with 100% positive results.
Sheibani had also earlier this year announced that the Iranian scientists managed to break Israel's monopoly by producing a new MS drug which makes Iranian patients needless of foreign medicines.
"Fortunately, the production monopoly on the drug was broken by Iran's pharmaceutical industries and is now being distributed in our country's drug market," he told reporters in March.
He also reiterated that the drug can be used even during pregnancy by ready-made injection syringe technology.
Also, Iran shattered the United States' monopoly in the production of the most important drugs in the treatment of MS in 2007.
Interferon beta 1, generically known as Ziferon, is mainly injected subcutaneously and has antiviral and immunomodulating properties. The drug is mainly used in the management of multiple sclerosis, although its mode of action is unclear.
####
For more information, please click here
Copyright © Fars News Agency
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Discoveries
Breaking carbon–hydrogen bonds to make complex molecules November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||